- Posts by Thomas J. JaworskiMember of the Firm
An accomplished trial attorney and former federal prosecutor, Thomas Jaworski* focuses on representing health care clients in complex litigation and government enforcement matters. Clients benefit from his insider knowledge ...
On May 12, 2025, the U.S. Department of Justice’s Criminal Division released a new guidance memo on white-collar enforcement priorities in the Trump Administration entitled “Focus, Fairness, and Efficiency in the Fight Against White-Collar Crime.” In this memo, and the accompanying speech by Matthew R. Galeotti, the Trump Administration’s appointed Head of the Criminal Division, the DOJ reiterated its previously stated commitment to prosecuting illegal immigration, drug cartels, and transnational criminal organizations. For the first time in the new Administration, however, the DOJ clearly articulated new white-collar enforcement priorities, directing Criminal Division white-collar prosecutors to follow three core tenets: focus, fairness, and efficiency. As detailed below, the new memo sets forth the following three priorities:
1. Focus on High-Impact Waste, Fraud, and Abuse Harming Vulnerable Taxpayers
It should be no surprise that the administration is targeting actors that profit through “waste, fraud, and abuse.” The memo sets clear priorities for its prosecutors to investigate, listing as the #1 priority health care fraud and federal program and procurement fraud. The memo goes on to provide a top 10 list of “high-impact areas”, with “trade and customs fraud, including tariff evasion” as #2. Heavy focus is given to fraud perpetrated by foreign actors and conduct threatening U.S. national security. Also listed is fraud victimizing U.S. investors, including elder fraud and Ponzi schemes. Appearing as #8 on the list is violations of the Controlled Substances Act and the Federal Food, Drug and Cosmetic Act, including the creation of counterfeit pills laced with fentanyl and the “unlawful distribution of opioids by medical professionals and companies.”
Blog Editors
Recent Updates
- Navigating the Legal Risks of Consumer Protection Claims in Healthcare
- Oregon SB 951, Regulating the Corporate Practice of Medicine, Is Signed into Law—But Changes May Be in the Works Already
- CMS Doubles Down on Medicare Advantage Recoupment: Announces Aggressive RADV Strategy to Reclaim Billions
- HealthBench: Advancing the Standard for Evaluating AI in Health Care
- What Health Care Lawyers and Professionals Need to Know About Emerging Employee Benefit Issues